SCHEMBL213141

SCHEMBL213141

CON=C(C)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.63
L3MBTL1 Q9Y468 2/20 0.63
MAPK1 P28482 2/20 0.63
HTT P42858 1/20 0.63
MAPT P10636 3/20 0.51
PKM P14618 1/20 0.51
CDK5 Q00535 1/20 0.51
CDK5R1 Q15078 1/20 0.51
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
HSD17B10 Q99714 1/20 0.45
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
TDP1 Q9NUW8 2/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.43
PPARA Q07869 1/20 0.42
ALDH1A1 P00352 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5732924 1.00 LMNA (0.63) LMNAL3MBTL1MAPK1HTTMAPT
SCHEMBL2615557 1.00 LMNA (0.63) LMNAL3MBTL1MAPK1HTTMAPT
SCHEMBL27927629 0.98 LMNA (0.61) LMNAL3MBTL1MAPK1HTTMAPT
SCHEMBL12750110 0.87 LMNA (0.48) LMNAL3MBTL1MAPK1HTTMAPT
SCHEMBL20997773 0.82 LMNA (0.59) LMNAL3MBTL1MAPK1HTTMAPT
SCHEMBL27622870 0.81 L3MBTL1 (0.63) LMNAL3MBTL1MAPK1HTTMAPT
SCHEMBL14480099 0.79 LMNA (0.61) LMNAL3MBTL1MAPK1HTTMAPT
SCHEMBL11209565 0.79 LMNA (0.61) LMNAL3MBTL1MAPK1HTTMAPT
SCHEMBL8220014 0.79 LMNA (0.42) LMNAL3MBTL1MAPK1HTTMAPT
SCHEMBL11209562 0.79 LMNA (0.61) LMNAL3MBTL1MAPK1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101985424-B Method for synthesizing o-nitroacetophenone compound UNIV ZHEJIANG TECHNOLOGY 2013-05-29 CN claimed
US-20120077941-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2012-03-29 US claimed
US-8088868-B2 oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis BRIDGESTONE CORPORATION (JP) 2012-01-03 US claimed
CN-101985424-A Method for synthesizing o-nitroacetophenone compound UNIV ZHEJIANG TECHNOLOGY 2011-03-16 CN claimed
US-20080146745-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2008-06-19 US claimed
CN-1187756-A Crop protection compositions CIBA GEIGY AG (CH) 1998-07-15 CN claimed
CN-114685393-A Novel oxime derivative, preparation method thereof and application thereof in agriculture 东莞市东阳光农药研发有限公司 2022-07-01 CN disclosed
EP-3227018-B1 CHELATION DIRECTED C-H ACTIVATION REACTIONS CATALYZED BY SOLID-SUPPORTED PALLADIUM(II) CATALYSTS UNIV VIRGINIA COMMONWEALTH (US) 2021-06-30 EP disclosed
CN-107739322-B Synthetic method of sulfonamide compound 济南大学 2020-06-23 CN disclosed
US-10000453-B2 Chelation directed C—H activation reactions catalyzed by solid-supported palladium(II) catalysts VIRGINIA COMMONWEALTH UNIVERSITY (US) 2018-06-19 US disclosed
US-20170362181-A1 CHELATION DIRECTED C-H ACTIVATION REACTIONS CATALYZED BY SOLID-SUPPORTED PALLADIUM(II) CATALYSTS VIRGINIA COMMONWEALTH UNIVERSITY 2017-12-21 US disclosed
EP-3227018-A1 CHELATION DIRECTED C-H ACTIVATION REACTIONS CATALYZED BY SOLID-SUPPORTED PALLADIUM(II) CATALYSTS Virginia Commonwealth University (US) 2017-10-11 EP disclosed
US-9656256-B2 N-heterocyclic carbene type palladium catalyst and its preparation method as well as applications SHANGHAI RESEARCH INSTITUTE OF CHEMICAL INDUSTRY CO., LTD. (CN) 2017-05-23 US disclosed
US-5231227-A Optically active hydroxybenzylamine derivative and process for producing said compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1993-07-27 US disclosed
EP-0311385-B1 OPTICALLY ACTIVE HYDROXYBENZYLAMINE DERIVATIVE, OPTICALLY ACTIVE AMINE-BORON COMPOUND CONTAINING SAID DERIVATIVE, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND BY USING SAID COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1993-02-03 EP disclosed
US-5120853-A Reacting optically active amine-boron complex with oxime or ketone to produce opotically active amine or alcohol compounds SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1992-06-09 US disclosed
CN-1052665-A The pyridinyl carbamates compound, and preparation method thereof and the Biocidal composition that is used to prevent and treat harmful organisms that contains them ISHIHARA SANGYO KAISHA (JP) 1991-07-03 CN disclosed
US-5011989-A Asymmetric reducing agents SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1991-04-30 US disclosed
CN-1036879-A BIOCIDE COMPOSITIONS ISHIHARA SANGYO KAISHA (JP) 1989-11-08 CN disclosed
EP-0311385-A2 Optically active hydroxybenzylamine derivative, optically active amine-boron compound containing said derivative, and process for producing optically active compound by using said compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1989-04-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362181-A1 CHELATION DIRECTED C-H ACTIVATION REACTIONS CATALYZED BY SOLID-SUPPORTED PALLADIUM(II) CATALYSTS WASF2, SCO2, SOD1 LMNA 3565/4885L3MBTL1 1181/4885MAPK1 1610/4885
US-10000453-B2 Chelation directed C—H activation reactions catalyzed by solid-supported palladium(II) catalysts WASF2, SOD1, CD274 LMNA 3454/4885L3MBTL1 1229/4885MAPK1 1600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.